secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2022-04-28T23:59:59+00:00
Accession:  0001104659-22-052317
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage settles wrongful death litigation; to issue $4M convertible preferred to HBIO
--------------------------------------------------------------------------------

- Biostage settles 2017 wrongful death suit; total costs estimated at ~$6M, $5.7M unpaid.
- HBIO to pay $4M of costs; Biostage will issue $4M of 8% convertible preferred stock.
- Preferred converts automatically upon qualified offering (e.g., NASDAQ uplisting or $4M+ private placement) at offering price.
- Remaining ~$1.7M in costs and future legal expenses still payable by Biostage or indemnified to HBIO.
- Neither party admits liability; claims dismissed with prejudice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000110465922052317/0001104659-22-052317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000110465922052317/tm2213848d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-052317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer